Basel, October 25, 2025 – Novartis announced today plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American College ...

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy ...

Introduction: A "2+1" TCE Specifically Designed for Autoimmune Diseases Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial ...

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren's disease to be presented Biomarker data informing use of investigational CAR-T cell therapy ...

Add articles to your saved list and come back to them any time. After going commercial in August and September with two medical diagnostic products, Proteomics International is now set to see a ...

Q3 net sales grew +7% (cc 1, +8% USD) and core operating income 1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta ...